Buscar
Mostrando ítems 1-10 de 225
Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol
(2002-07-08)
Flavopiridol has been shown to potently inhibit CDK1 and 2 (cyclin-dependent kinases 1 and 2) and most recently it has been found that it also inhibits CDK9. The complex CDK9-cyclin T1 controls the elongation phase of ...
Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol
(2002-07-08)
Flavopiridol has been shown to potently inhibit CDK1 and 2 (cyclin-dependent kinases 1 and 2) and most recently it has been found that it also inhibits CDK9. The complex CDK9-cyclin T1 controls the elongation phase of ...
Immunohistochemical Expression of p16, p21, p27 and Cyclin D1 in Oral Nevi and Melanoma
(Springer, 2012)
The acquisition of abnormalities at G1/S is considered a crucial step in the genesis and progression of melanoma. The expression of cell cycle regulators has also been used in various neoplasms as an adjunct to diagnosis. ...
Meridianins, a new family of protein kinase inhibitors isolated from the Ascidian Aplidium meridianum
(Pergamon-Elsevier Science Ltd, 2004-04)
Meridianins are brominated 3-(2-aminopyrimidine)-indoles which are purified from Aplidium meridianum, an Ascidian from the South Atlantic (South Georgia Islands). We here show that meridianins inhibit various protein kinases ...
Structural Basis for Interaction of Inhibitors with Cyclin-Dependent Kinase 2
(Bentham Science Publ Ltd, 2005-01-01)
Cell cycle progression is tightly controlled by the activity of cyclin-dependent kinases (CDKs). CDKs are inactive as monomers, and activation requires binding to cyclins, a diverse family of proteins whose levels oscillate ...
Structural Basis for Interaction of Inhibitors with Cyclin-Dependent Kinase 2
(Bentham Science Publ Ltd, 2005-01-01)
Cell cycle progression is tightly controlled by the activity of cyclin-dependent kinases (CDKs). CDKs are inactive as monomers, and activation requires binding to cyclins, a diverse family of proteins whose levels oscillate ...
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
(2018)
Background
To compare the efficacy and toxicity of the combination of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and nonsteroidal aromatase inhibitors (AI) versus AI alone as first-line therapy for patients with ...
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
(2018)
Background
To compare the efficacy and toxicity of the combination of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and nonsteroidal aromatase inhibitors (AI) versus AI alone as first-line therapy for patients with ...